Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis

International Journal of Technology Assessment in Health Care

Volumn 16, Issue 3, 2000, Pages 768-780

  Kobelt, Gisela ^a   Jönsson, Linus ^b   Henriksson, Freddie ^c   Fredrikson, Sten ^d   Jönsson, Bengt ^c  

^a Health Dynamics International   (Sweden)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c Centre for Health Economics

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost utility; Interferon beta 1b; Modeling; Secondary progressive MS

Indexed keywords

INTERFERON BETA SERINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISABILITY; DISEASE COURSE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MODEL; MULTIPLE SCLEROSIS; QUALITY ADJUSTED LIFE YEAR; SWEDEN;

EID: 0033805261     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462300102041     Document Type: Article

References (33)

1. Akademiska Sjukhuset
2. The economics of multiple sclerosis: A cost of illness study
3. Survival of patients with multiple sclerosis in Denmark: A nationwide long-term epidemiologic survey
4. The Canadian Burden of Illness Group Burden of illness of multiple sclerosis, part 1: Cost of illness
5. The Canadian Burden of Illness Study Group Burden of illness in multiple sclerosis, part 2: Quality of life
6. The value of health: 1970-90
7. The EuroQol Group. EuroQol: A new facility for the measurement of health-related quality of life
8. The European Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b delays progression of disability in secondary progressive multiple sclerosis: Results of a European multicentre randomised study
9. FASS. Lakemedel i Sverige (Pharmaceutical lexicon)
10. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis
11. Multiple sclerosis and other demyelinating diseases
12. The economic cost of multiple sclerosis in Sweden in 1994
13. The cost of multiple sclerosis
14. Discounting in economic evaluation of health care interventions
15. Rating neurological impairment in multiple sclerosis and expanded disability status scale (EDSS)
16. Impairment, disability and handicap in multiple sclerosis. A cross-sectional study in More and Romsdal County, Norway
17. Economic evaluation of multiple sclerosis in the UK, Germany and France
18. US and UK health economics: Two disciplines separated by a common language?
19. Treatment of multiple sclerosis with interferon beta-1b: An appraisal of cost-effectiveness and quality of life
20. A cost-utility analysis of interferon beta for multiple sclerosis
21. The cost effectiveness of life saving interventions in Sweden
22. Markov models in medical decision making
23. The natural history of multiple sclerosis: A geographically based study